From Yahoo Finance: 2025-05-21 11:21:00

aTyr Pharma, Inc. (ATYR) is highlighted as a top multibagger stock with a 485% upside potential in the next 12 months. The company focuses on innovative medicines for interstitial lung diseases, with their lead candidate, Efzofitimod, showing promise in clinical trials to reduce inflammation and improve lung function.

aTyr Pharma’s partnership with Kyorin Pharmaceutical in Japan strengthens their global presence. With $88 million in cash and 63% of analysts rating ATYR as a “Strong Buy,” the stock is projected to reach $18.55 in the next year, indicating a 485.17% upside potential. Despite ranking 6th on the list, some AI stocks are seen as more promising for higher returns.

Read more: Analysts See 485% Upside Potential